We are live on ! Find out more
WST icon

West Pharmaceutical

366.00 USD
+2.73
0.75%
At close Updated Oct 9, 4:00 PM EDT
Pre-market
After hours
366.00
0.00
0%
1 day
0.75%
5 days
0.36%
1 month
8.62%
3 months
2.33%
6 months
41.56%
Year to date
32.42%
1 year
38.86%
5 years
-9.31%
10 years
384.13%
 

About: West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Employees: 10,800

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 68.8%
Neutral 28.1%
Negative 3.1%
Neutral
PRNewsWire
3 days ago
West to Host Third-Quarter 2026 Conference Call
EXTON, Pa., Oct. 8, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release third-quarter financial results before the market opens on Thursday, October 29, 2026, and will follow with a conference call to discuss the results and business expectations at 8:00 a.m. Eastern Time.
West to Host Third-Quarter 2026 Conference Call
Positive
Seeking Alpha
4 days ago
West Pharma: Still A Buy, But Expectations Are Rising
West Pharmaceutical Services remains a buy despite a demanding valuation, driven by new growth catalysts and robust financial performance. Double-digit growth from GLP-1s, HVP upgrades, and the multiyear Annex 1 regulatory opportunity underpin WST's bullish outlook. Annex 1 upgrades represent a multiyear, regulatory-driven mix shift, with only ~1B of a 6B component opportunity converted so far.
West Pharma: Still A Buy, But Expectations Are Rising
Positive
Seeking Alpha
13 days ago
Best Dividend Aristocrats For October 2026
The ProShares S&P 500 Dividend Aristocrats ETF trails SPY YTD, but 20 individual Aristocrats are outperforming the ETF. Dividend growth among Aristocrats in 2026 averages 4.43%, with notable increases from Nordson (14.63%) and McDonald's (3.76%) in the past month. 36 Aristocrats currently screen as potentially undervalued, each with an estimated long-term annualized return of at least 10%.
Best Dividend Aristocrats For October 2026
Negative
Zacks Investment Research
23 days ago
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical's biologics exposure, Annex 1 projects and delivery-device growth support prospects despite near-term headwinds.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Neutral
Seeking Alpha
27 days ago
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
1 month ago
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
West Pharmaceutical Services, Inc. (WST) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Positive
Seeking Alpha
1 month ago
Best Dividend Aristocrats For September 2026
Dividend Aristocrats, tracked via NOBL, delivered a 12.9% YTD return, closely trailing SPY's 13.68%, with 29 Aristocrats outperforming SPY in 2026. Top 2026 performers include TGT (+73.04%), NUE (+55.64%), and BEN (+49.25%), highlighting strong sectoral momentum among select Aristocrats. Six Aristocrats announced dividend increases in the past month, pushing the group's average 2026 dividend growth rate to 4.30%, up from 4.10% last month.
Best Dividend Aristocrats For September 2026
Neutral
PRNewsWire
1 month ago
West to Participate in Upcoming Investor Conferences
EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.
West to Participate in Upcoming Investor Conferences
Positive
Zacks Investment Research
1 month ago
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.
WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
Positive
Zacks Investment Research
1 month ago
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
West Pharmaceutical (WST) Upgraded to Buy: Here's Why
Price charts implemented using Lightweight Charts™